# EDGAR Filing Document

**Accession Number:** 0001933414
**File Stem:** 0001628280-23-002542
**Filing Date:** 2023-2
**Character Count:** 3002
**Document Hash:** b943461e8c822170ef2cbf12c1529020
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-23-002542.hdr.sgml**: 20230310

**ACCESSION NUMBER**: 0001628280-23-002542

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230207

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Mineralys Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001933414
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087
- **BUSINESS PHONE:** (888) 378-6240

**MAIL ADDRESS:**
- **STREET 1:** 150 N. RADNOR CHESTER ROAD
- **STREET 2:** SUITE F200
- **CITY:** RADNOR
- **STATE:** PA
- **ZIP:** 19087

February 7, 2023

Office of Life Sciences

Division of Corporation Finance

U.S. Securities and Exchange Commission

100 F Street N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Mineralys Therapeutics, Inc.** |
| | **Registration Statement on Form S-1, as amended** |
| | **File No. 333-269282** |

---

Ladies and Gentlemen:

In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the "<u>Act</u>"), we hereby join in the request of Mineralys Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Thursday, February 9, 2023, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 4,210 copies of the Preliminary Prospectus dated February 2, 2023 (the "<u>Preliminary Prospectus</u>") through the date hereof, to underwriters, dealers, institutions and others.

In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.

Very truly yours,

BOFA SECURITIES, INC.

EVERCORE GROUP L.L.C.

STIFEL, NICOLAUS & COMPANY, INCORPORATED

As Representatives of the several underwriters

[*Signature Pages Follow*]

------

---

| | |
|:---|:---|
| BOFA SECURITIES, INC. | BOFA SECURITIES, INC. |
| By: | /s/ Gerardo Ubaghs |
|  | Name: Gerardo Ubaghs |
|  | Title: Managing Director |
| EVERCORE GROUP L.L.C. | EVERCORE GROUP L.L.C. |
| By: | /s/ Gloria Tang |
|  | Name: Gloria Tang |
|  | Title: Managing Director |
| STIFEL, NICOLAUS & COMPANY, INCORPORATED | STIFEL, NICOLAUS & COMPANY, INCORPORATED |
| By: | /s/ Kenneth Clausman |
|  | Name: Kenneth Clausman |
|  | Title: Managing Director |

---

As representatives of the several underwriters

cc: Ilir Mujalovic, *Shearman & Sterling LLP*

[*Signature Page to Acceleration Request Letter*]